MACSima™ Imaging Platform

Unlock the next level in immuno-oncology research

Immuno-oncology (IO) as a research field has grown tremendously in recent years as researchers the world over try to understand and manipulate the immune response within the tumor microenvironment in the continuing fight against cancer.

The deep phenotyping of tumor cells in the tumor microenvironment can help define new targets to be used in promising IO therapies. Current tools demand a tradeoff between spatial information and the number of markers that can be analyzed. With the MACSima Imaging Platform, no such sacrifice is necessary: hundreds of markers on a single sample can be stained in an automated manner, while preserving tissue integrity and capturing the spatial context, opening new possibilities for advances in IO research.

In action in IO

Hot off the press

Predicting immunotherapy response in lung cancer

In their recent paper published in Nature Commmunications, Clemens Hinterleitner et al. discovered that platelets expressing PD-L1 (pPD-L1) interact with lung cancer cells and that the expression level of PD-L1 can predict responses in immunotherapy for non-small cell lung cancer (NSCLC). Using the MACSima Imaging Platform they confirmed that NSCLC samples with high pPD-L1 levels show lower numbers of T cells in the tumor microenvironment and less infiltrating T cells.

Read the paper
Publication in Nature Communications

Discovery of CAR target candidates in pancreatic carcinoma

A new publication in Nature Communications reveals target candidates for CAR T cell–based immunotherapy of pancreatic adenocarcinoma. A research team from across Germany, led by Miltenyi Biotec, used a smart combination of data mining, flow cytometry, and ultrahigh-content analysis with the MACSima Imaging Platform to bypass a major roadblock preventing potential cellular immunotherapy: the lack of suitable tumor-specific antigens. Check out the full story at Nature Communications.

Read the paper
Peer-reviewed publication

New potential target pair for cell therapy of ovarian carcinoma

Ali Kinkhabwala et al. used MICS (MACSima Imaging Cyclic Staining) technology to analyze human glioblastoma, ovarian and pancreatic carcinoma, as well as 16 healthy tissues. Showing that EPCAM and THY1 are co-expressed only on ovarian cancer cells, but not on healthy tissue, they identified a new potential target pair for CAR T cell–based therapy. Validation with CAR T cells showed efficient killing of double-positive cells only, suggesting a reduced toxicity of CAR T cells. Kinkhabwala, A. et al. (2022) Sci. Rep. 12: 1911. Licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Read the paper
The MACSima Platform will greatly boost our pre-clinical research and transform our understanding of each individual cancer. Ultimately, these results will enhance our options for personalized medicine as well as the way we will treat our patients.
Christian Seitz, M.D.
Pediatrician at the University Children’s Hospital Tübingen, 
Tübingen, Germany
At OHSU, we have been developing methods for high-content imaging for many years, and our partnership with Miltenyi is allowing us to move at a much accelerated pace. The MACSima Instrument will be an essential tool for identifying the spatial and molecular compositions of tumors and their microenvironments that are important in tumor genesis, progression and/or response to treatment.
Joe Gray, Ph.D.
Professor of Biomedical Engineering at OHSU, School of Medicine
Portland, OR, USA
I am thrilled about the MACSima Instrument and its technology! The MACSima System will revolutionize our understanding of tumor immunology.
Prof. Dr. Rupert Handgretinger 
University Children’s Hospital Tübingen
Tübingen, Germany 

See how it works

Video

Powerful and automated: Ultra high content imaging with the MACSima™ Imaging Platform

Learn how the MACSima Imaging System can stain hundreds of markers on a single sample, and stain multiple samples at a time, all in an entirely automated fashion. See more than ever before: Unlock new insights and advance your research further, faster!

Try for yourself with our Art Tool:
Select the tissue type of your interest and up to six markers to create your own image with data taken from real-life samples.

Get further information on the MACSima Imaging Platform